A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation

Recruiting now · Not applicable

Conditions studied: ECMO

In brief

ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.

Key facts

Study ID

NCT06676085

Run by

Beijing Chao Yang Hospital

People needed

140

Starts

2024-11-01

Expected to finish

2027-12-31

Last updated by the study team

2026-06-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age older than 18 years old
• received ECMO because of severe respiratory failure

You may not qualify if…

• anticoagulant contraindications
• cerebral infarction or suspected patients
• severe hypertension
• women in gestational and lactational period
• hemophilia
• allergic to heparin or Nafamostat
• unwilling or unable to complete the study

Where it is running

• Bing Sun — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.